Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Nimesulide Suspension
Notice type:
Warning
Date:
15/05/2007
Product name or type:
Aulin 100mg Tablets;Aulin 100mg Granules;Mesulid 100mg Granules;Mesulid 100mg Tablets; Mesine 100mg Tablets;Aulin 100mg Tablets;Aulin 100mg Granules;Aulin 100mg Tablets
Active Substance:
Nimesulide
Product Classification:
non-steroidal anti-inflammatory
Prescription Required:
Yes
Problem Or Issue:
IMMEDIATE SUSPENSION OF THE MARKETING OF MEDICINES CONTAINING NIMESULIDE
The Irish Medicines Board [IMB] today announced the suspension of the marketing and sale of nimesulide-containing medicinal products for oral use available in Ireland, with immediate effect.
The products concerned are:
Product Name Marketing Authorisation Number
Aulin 100mg Tablets PA 294/18/1
Aulin 100mg Granules PA 294/18/2
Mesulid 100mg Granules PA 915/1/1
Mesulid 100mg Tablets PA 915/1/2
Mesine 100mg Tablets PA 281/111/1
Aulin 100mg Tablets PPA 465/110/1
Aulin 100mg Granules PPA 1328/51/1
Aulin 100mg Tablets PPA 1328/51/2
Nimesulide is a non-steroidal anti-inflammatory medicine that is authorised in Ireland since 1995 for the treatment of acute pain, the symptomatic treatment of painful osteoarthritis and for primary dysmenorrhoea [period pains]. It is available only on prescription.
Liver damage is a rare but serious adverse effect known to occur with nimesulide and the IMB has previously issued advice to healthcare professionals regarding this risk. The IMB has now been provided with information from the National Liver Transplant Unit at St. Vincent’s University Hospital on six patients who required liver transplant following treatment with nimesulide. Since nimesulide was first licensed in Ireland in 1995, a total of 53 liver-related adverse reaction reports have been received. This includes 9 cases of liver failure, 6 of which originated from the National Liver Transplant Unit. Three cases of liver failure resulted in a fatal outcome and the IMB is aware of one additional liver-related fatality.
The IMB has notified the medicines regulatory authorities through Europe and has initiated a review of the safety of nimesulide-containing products.
Actions To Be Taken:
Advice to patients/consumers:
-
Stop taking the medicine immediately.
- Return to your doctor for a review of your condition and further advice.
- Return any remaining packs (unused or partially used) of the above products to your pharmacist
.
The IMB is working to inform all patients, doctors, and pharmacists of this issue and has instructed the relevant companies to recall their products from all patients / consumers, pharmacies, hospitals and wholesalers immediately.
Further Information:
For further information, including a
Questions and Answers
document, is available here.
The
Press Release
is also available for download.
Patients and healthcare professionals who have any queries can contact the IMB on the following helpline numbers:
Freephone 1-800-251054 or 01-6343555.
FOR INFORMATION:
Winifred McCourt / Angie Grant Weber Shandwick
Tel: (01) 676 01 68 or 087 244 6004 / 086 377 2791
« Back
Date Printed: 20/04/2024